Introduction
Considerable advances in the field of anti-tumor immunotherapy have resulted in promising strategies for the treatment of malignancies. More recently, it has led to the first Food and Drug Administration approved clinical application that uses an autologous dendritic cell-based strategy. Various approaches have been developed, such as the administration of tumor peptides or epitopeenhanced peptides, 1,2 naked DNA expression plasmids, 3 pulsed dendritic cells 4, 5 and the use of whole tumor cells. 6, 7 Autologous tumor cells contain all the tumorassociated antigens, rendering their application interesting in avoiding the isolation of one specific epitope and allowing a broader anti-tumor immune response.
Allogeneic tumor cells have also been extensively studied, but their survival in the recipient is short as they are quickly eliminated by the host immune response (human leukocyte antigen-dependent and innate natural killerdependent mechanisms). Furthermore, allogeneic tumor cells may not have the necessary antigens to stimulate a specific immune response against the host's own tumor.
To enhance the host immune response, autologous or allogeneic tumor cells have been genetically engineered to produce various cytokines. 8 This strategy was applied in several cell-based vaccination trials in animal models and was evaluated for the immunomodulating activities or adjuvant effects of the cytokines on tumor rejection. [9] [10] [11] [12] [13] [14] Granulocyte-macrophage colony-stimulating factor (GM-CSF) was revealed to have a potent stimulation effect on cells at the immunization site, enhancing the tumorassociated antigens' processing and presentation to CD4 þ and CD8 þ T cells. 15 This approach has been shown to induce potent, specific and long-lasting antitumor immunity in mice previously vaccinated with GM-CSF-producing irradiated tumor cells, leading to the rejection of small tumor burden of melanoma cells and lung, colon and renal cancer cells. 10 The use of ex vivo genetically modified tumor cells producing GM-CSF as an immunization method has been extended to a variety of animal tumor models, such as leukemia, 16 melanoma 17 and glioma. 18 Furthermore, preclinical and clinical trials, including patients suffering from renal cell carcinoma, 19 melanoma, 20, 21 prostate cancer, 22 pancreatic cancer 23 or non-small-cell lung cancer, 24, 25 have also been performed. These promising studies have demonstrated the ability of GM-CSF to induce an efficient anti-tumor immune response when produced locally at the tumor cell injection site, and displaying minimal toxicity and no systemic adverse reaction. The autologous approach, however, imposes a requirement for individualized genetic engineering of autologous tumor cells leading to unpredictable levels of GM-CSF secretion.
To circumvent these limitations, a strategy for genetically modifying an allogeneic cell line that can act as a bystander cytokine producer at the vaccination site, was developed. The immunization is then performed by co-injection of the bystander cells and unmodified autologous tumor cells. In a mouse model, a major histocompatibility complex-negative allogeneic cell line genetically engineered to produce GM-CSF was shown to afford an anti-tumor immune response that was equivalent to or better than those achieved using genetically modified autologous tumor cells. 26 Furthermore, the investigators reported the generation of the modified K562 human erythroleukemia cell line, which produces large quantities of GM-CSF, for use in clinical applications. However, using allogeneic tumor cells engineered to produce a stable amount of the cytokine leads to the rapid destruction of the cells, and it does not allow for a sustained delivery of the adjuvant over several days. Recently, a phase III clinical trial in prostate cancer was prematurely terminated after analysis of the early data. In addition, the immune response against the newly exposed allogeneic antigens of the bystander cell line rather than the desired tumor-associated antigens potentially skews the immune reaction. From a clinical point of view, an ideal immunotherapy approach should combine the benefits outlined above, and a prolonged and predictable release of the immunmodulatory molecule at the injection site, and the ability to remove the source of cytokine production in case of side effects. Cell encapsulation technology may satisfy these criteria by allowing cell transplantation across an immunological barrier and preventing the contact between the encapsulated cells and the host immune cells. In addition, the properties of the permeable membrane of the capsule ensures a selective influx of molecules essential for cell survival, and a selective outflow of metabolic byproducts and the cytokine of interest. This strategy has been studied extensively as a sustained delivery system to provide biologically active molecules like erythropoietin, [26] [27] [28] [29] coagulation factors 30 and neurotrophic factors. 31, 32 Clinical trials have been conducted in diabetic patients 33 and patients suffering from amyotrophic lateral sclerosis. 34 Further studies of the biomaterial compatibility 35 and the host immune reaction, to obtain long-term encapsulated cells survival, 29, 36 have been carried out.
Here, we report the development of a novel strategy for clinical anti-tumor immunotherapy using a physically immuno-isolated GM-CSF-producing bystander cell line enclosed into hollow fiber macrocapsules.
Materials and methods

Cell lines
The K562 cell line is a human erythroleukemia cell line 37 supplied by the American Type Culture Collection (ATCC, Rockville, MD). K562 cells were cultured in RPMI 1640 medium (GIBCO-BRL, Life Technologies, Baltimore, MD), supplemented with 10% fetal calf serum, 50 U ml -1 penicillin-streptomycin, 2 mM L-glutamine and grown in suspension culture at 37 1C in a 5% CO 2 humidified environment. K562-hGM-CSF cells were obtained by transfecting K562 cells using the standard calcium phosphate precipitation method with the pUCMDhGM-CSF plasmid and the puromycin resistance genecontaining pJ6Omega-puro plasmid. K562-hGM-CSF cells were selected in culture medium containing 2 mg ml -1 puromycin (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). A master cell bank and clinical production lots were tested for sterility (Harvard Gene Therapy Initiative, Harvard Medical School, Boston, MA).
The B16 mouse melanoma cell line was obtained from ATCC and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 50 U ml -1 penicillin-streptomycin. B16 cells were genetically modified for the expression of mGM-CSF using retroviral-mediated gene transfer, as previously described. 38 
Capsule design
One-centimeter long macrocapsules were obtained by cutting hollow fibers of polyethersulfone (Azko Nobel Faser, Wupperthal, Germany) with a molecular weight cut-off of 280 kDa, an external diameter of 720 mm and an internal diameter of 524 mm. Before cell loading, syringe hub adaptors were glued to one extremity with a photopolymerizable acrylate-based glue (Luxtrack LCM 23, Notestik, Electronic Materials and Adhesives, Rancho Dominguez, CA) illuminated for 30 s at a wavelength of 460 nm. For encapsulation of adherent cells, such as B16 cells, scaffold matrices were inserted into capsules. The matrices were obtained from a polyvinyl alcohol sponge provided by Rippey Corporation (El Dorado Hills, CA) using a hollow drill with an internal diameter corresponding to the inner dimensions of the capsule. The polyvinylalcohol rods were washed in sterile ultra-pure water, dried at room temperature and inserted into the polyethersulfone capsules before sealing the extremity with the acrylate-based glue. The fibers were finally sterilized with ethylene oxide at 55 1C and kept 10 days at room temperature to eliminate any traces of gas. Capsules designed for human application were cut at a length of 2 cm, and were reinforced by insertion of a titanium coil grade 2 (0.2 Â 0.1 mm) (Heraeus, Cossonay, Switzerland) into the capsule.
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Cells were diluted with culture medium to obtain a suspension of 10 4 cells ml -1 . Using a 50 ml syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) fitting the adaptor hub, 10 ml or 20 ml of cell suspensions (10 5 or 2 Â 10 5 cells) were injected into a 1-cm or 2-cm long microporous membrane, respectively. The hub adaptor was cut-off, and the extremity of the capsule sealed as described above. The loaded capsules were kept in culture medium at 37 1C in a 5% CO 2 humidified environment for the duration of the experiment. The culture medium was replaced three times a week.
Capsules freezing and thawing
After loading of the K562-hGM-CSF cells, the capsules were maintained in culture medium at 37 1C in a 5% CO 2 humidified environment for 1 or 3 days before freezing.
At that time, capsules were placed in small silicone tubes (Socochim SA, Lausanne, Switzerland) measuring 2.5 cm in length with an internal diameter of 3 mm and an outer diameter of 3.8 mm. These tubes had previously been sealed at one end with the acrylate-based glue as described above and sterilized with ethylene oxide at 55 1C. Tubes were filled with approximately 300 ml of culture medium supplemented with 10% dimethylsulfoxide (Axon Lab AG, Baden-Daettwil, Switzerland) and placed vertically in conventional tubes for cell storage without culture medium. The capsules were then frozen using an automated freezer with a program cooling 1 1C min
The thawing procedure consisted of placing the silicone tubes in six-well culture dishes containing complete culture medium at 37 1C. After extraction of the capsules from the silicone tubes, they were rinsed with culture medium and placed in 12-well dishes at 37 1C in a 5% CO 2 humidified environment.
Cells and capsules release of GM-CSF K562-hGM-CSF or B16-mGM-CSF cells were plated at a density of 10 5 cells per well in six-well dishes containing 1 ml of culture medium. After 2 h, culture medium was harvested and centrifuged (4 min, 1400 revolutions per min). Supernatant was filtered through 0.22 mm filters and stored frozen at À20 1C. K562-hGM-CSF-or B16-mGM-CSF-containing capsules were periodically tested for their ability to secrete GM-CSF by placing them in 12-well dishes with 1 ml culture medium. After 2 h, culture medium was harvested and stored frozen at À20 1C. The same procedure was repeated with cells and capsules after irradiation (10 000 rads from a 137 Cs source) to evaluate the GM-CSF production and the cell survival. GM-CSF was quantified using ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Capsule implantation in mice
Adult female BALB/c mice (Charles River Laboratories, Saint-Germain sur l'Abresle, France), were anesthetized by inhalation of isoflurane (Forene, Abbott Ireland, Sligo, Republic of Ireland). Animals were placed in a back position for surgery. The capsules were ventrally implanted in a subcutaneous and extra-peritoneal location through a 14G Abbocath catheter (Abbott). The entry site in the skin was closed using a non-resorbable suture (Prolene 6/0, Johnson and Johnson Intl, European Logistics Center, Brussels, Belgium). On recovery, the animals were returned to the animal care facility where they had access to food and water ad libitum. The experiments were performed according to a protocol approved by our local Committee on Animal Experimentation, in agreement with Swiss Federal Law.
Capsule histology
Capsules intended for histological analysis were fixed in 4% paraformaldehyde with 1% glutaraldehyde for a minimum of 3 h. They were then dehydrated through grading alcohol bath cycles and embedded in glycolmethacrylate (Leica Instruments, Nussloch, Germany). Capsules were cut at a thickness of 4 mm and stained with hematoxylin and eosin (Papanicolaou, Merck KgaA, Darnstadt, Germany).
Statistical analysis
Results are shown as the mean±s.e.m. The results obtained were analyzed for statistical significance between the various groups using a Student's t-test. A P-value o0.05 was considered statistically significant.
Results
Generation of the K562-hGM-CSF and the B16-mGM-CSF cell lines
The human erythroleukemia cell line K562 was used for the generation of an hGM-CSF-producing bystander cell line. GM-CSF secretion from these cells was quantified and repeated three times. A secretion of 2992±49 ng GM-CSF per 10 6 cells every 24 h was obtained. In terms of safety regarding the use in clinical applications, it is recommended that cell replication be limited by irradiation. Following irradiation with 10 000 rads, daily GM-CSF release studies and assessments of the viable cell count using the Trypan blue vital coloration assay, were performed. The results indicated a decrease in GM-CSF production from 3216 ± 235 ng GM-CSF per 10 6 cells every 24 h 1 day after cell irradiation to 2 ± 0 ng GM-CSF per 10 6 cells every 24 h after 14 days (n ¼ 4) (data not shown). The cell viability also showed a decrease in approximately 95% over the same 14-day period (data not shown). The benefit of the development of a bystander cell line is that the modified cells can be used for many applications. In contrast, immunotherapeutic approaches based on individualized genetic engineering of autologous tumor cells can only be used for one application. Therefore, a K562-hGM-CSF cell line was engineered and tested in the experiments described below.
GM-CSF secretion from capsules containing K562-hGM-CSF cells K562-hGM-CSF cells were enclosed into 1-cm long hollow fiber macrocapsules at a density of 10 5 cells per capsule. As the sustained release of GM-CSF over several days is essential for use in potential clinical applications, (Figure 1 ).
GM-CSF secretion from K562-hGM-CSF capsules after freezing and thawing
For the use in clinical applications, it is crucial to be able to produce large quantities of loaded capsules and to store them safely. For these reasons, we tested whether or not the encapsulated cells could be frozen and stored. We evaluated capsule freezing at two post encapsulation times. One group of capsules was frozen 1 day (group A) and another group 3 days (group B) after K562-hGM-CSF cells encapsulation (10 5 cells per capsule). Both groups were compared with a control group described above consisting of capsules loaded with K562-hGM-CSF cells but not submitted to the freezing/thawing procedure (group C). Groups A and B were thawed after several days at À80 1C and maintained in culture under the same conditions as group C. GM-CSF release measurements were performed at day 1, 3, 5, 8, 15 and 25 after capsule thawing. At each time point, one to three capsules were fixed for histological analysis after the GM-CSF release procedure. The results showed secretion of GM-CSF through day 25 with 553±251 ng GM-CSF per capsule every 24 h for group A and 703±82 ng GM-CSF per capsule every 24 h for group B (Figure 2) . Frozen capsules had a lower secretion capacity immediately after thawing, but recovered to comparable values with the control group after 8 days in culture (group A 1174 ± 145, group B 1137 ± 115 and group C 1298 ± 149 ng GM-CSF per capsule every 24 h). Comparing the results from groups A and B, we observed lower values for group A than for group B that were statistically significant until day 8. After day 8, both groups reached a similar secretion capacity. Furthermore, group B capsules had a higher GM-CSF secretion before the freezing procedure than capsules from group A. Histological analysis showed cell survival in the capsules, although some necrotic debris appeared over time (Figure 3 ).
GM-CSF secretion from K562-hGM-CSF capsules after irradiation
Capsules containing K562-hGM-CSF cells were tested for their secretion ability after an irradiation procedure of 10 000 rads (n ¼ 4) in a similar manner to the nonencapsulated cells. The results indicated a decrease in GM-CSF production over a period of 14 days with a GM-CSF secretion value of 895 ± 33 ng per capsule every 24 h 2 days after the irradiation procedure, and reaching 13±1 ng per capsule every 24 h after 14 days in vitro (data not shown).
GM-CSF secretion from K562-hGM-CSF capsules after irradiation and freezing/thawing K562-hGM-CSF capsules were submitted to irradiation and freezing/thawing procedures. Then their ability to secrete GM-CSF over time was evaluated according to the sequence of the procedures. Capsules containing 10 5 K562-hGM-CSF cells were either irradiated and immediately frozen (group A, Figure 4a ), or frozen first, then thawed and maintained in culture medium for 1 day followed by irradiation (group B, Figure 4b ). Before the procedures, groups A and B showed similar secretion values of 1007±99 and 1120±70 ng GM-CSF per capsule every 24 h, respectively. After the procedures, groups A and B again showed similar results at 24 h, with secretion values of 487±52 ng GM-CSF per capsule every 24 h and 520 ± 19 ng GM-CSF per capsule every 24 h, respectively. A higher decrease in GM-CSF secretion after 7 days was observed for group A (188±45) than for group B (355 ± 22) (P ¼ 0.006).
GM-CSF secretion from K562-hGM-CSF capsules designed for human application
For future human application, we tested the K562-hGM-CSF cells with the clinical grade capsules. These capsules were designed to have a length of 2 cm and were reinforced with a titanium coil (Figure 5a ). They were loaded with 2 Â 10 5 K562-hGM-CSF cells and maintained in culture for 3 days before irradiation and freezing procedures (n ¼ 4) were performed. The GM-CSF secretion was quantified over a 7-day period after thawing. The results showed a GM-CSF production of 3860 ± 460 ng In vivo survival of encapsulated K562 cells K562 cells were loaded into capsules at the same cell density as previously described. After 3 days in vitro, capsules were implanted in mice in a ventral subcutaneous extra-peritoneal location. After 5 days, capsules were retrieved and histological analysis was performed. Results showed that encapsulated K562 cells are able to survive for 5 days under xenogeneic conditions ( Figure 6 ).
In vivo implantation of encapsulated B16-mGM-CSF cells
As a preliminary test for the in vivo application of the cell encapsulation strategy for anti-tumor immunotherapy, the biological activity of encapsulated GM-CSF-secreting cells was evaluated under allogeneic conditions by assessing the local inflammatory reaction at the implantation site. The B16-mGM-CSF cells used in the experiments secreted 2644 ± 197 ng GM-CSF per 10 6 cells every 24 h (n ¼ 4). Capsules were loaded with B16-mGM-CSF or unmodified B16 cells as a control. In vitro secretion tests showed stable cytokine production over 25 days (data not shown). The pre-implantation cytokine secretion values were 153±11 ng GM-CSF per capsule every 24 h (n ¼ 8). Capsules were retrieved after 3 days in vivo and the site of implantation, and the capsules with the surrounding tissue, were evaluated. Mice implanted with B16-mGM-CSF capsules showed a pericapsular inflammatory reaction that was not observed in mice implanted with non-secreting capsules (Figure 7) . Figure 4 Time course of GM-CSF secretion from K562-hGM-CSF capsules following irradiation with 10 000 rads and freezing and thawing (a) (n ¼ 3), or freezing and thawing followed by irradiation (b) (n ¼ 6).
Cell encapsulation for cancer immunotherapy
F Schwenter et al
Discussion
In this study, we report the development of a novel strategy for anti-tumor immunotherapy using human GM-CSF-producing cells enclosed into hollow fiber capsules. This device was designed for implantation in close proximity to autologous tumor cells that act as the richest source of tumor antigens. Such co-implantation should enhance dendritic cell recruitment and activation of a potent stimulation of the anti-tumor immune response.
Cell encapsulation of several proteins such as erythropoietin and neurotrophic factors has been extensively reported in in vitro, in vivo and clinical studies. 29, 33, 36 This technology was developed as a replacement strategy for long-term protein release. In such applications, a critical requirement was to achieve the lowest inflammatory response around the capsule to avoid deleterious effects for encapsulated cells and allow for a long-term release of Immunoglobulins as well as smaller inflammatory and cytotoxic agents may diffuse through the membrane and cause immune toxicity, 39, 40 which can be an issue for long-term application of the encapsulation technology for therapeutic proteins production. The device developed in this study was aimed at inducing a strong local inflammatory reaction for a limited period of time and results indicated a preserved cell survival over a 25-day period, which is more than expected for antitumor immunotherapy application.
The secretion of GM-CSF should result in an ideal milieu for triggering an anti-tumor immune response. This immunostimulatory strategy has been widely studied in murine models and phase I clinical trials using irradiated tumor cells genetically engineered to produce GM-CSF. 10, 15, 19, [21] [22] [23] [41] [42] [43] The inability to obtain reproducible levels of the cytokine, and the labor-intensive requirements for individualized genetic engineering, led to the development of allogeneic bystander cells for the local delivery of GM-CSF, such as the K562 human erythroleukemia cell line. [44] [45] [46] However, despite their undetectable expression of human leukocyte antigen class I and II, the high sensitivity of allogeneic K562 cells to natural killer cytotoxicity prevented continuous release of the cytokine for several days. In this context, the encapsulation technology has the advantage of allowing a sustained release of the cytokine at the implantation site by the allogeneic cells being physically isolated from the host immune response.
The K562-hGM-CSF cell line was obtained after transfection using the standard calcium phosphate method of the GM-CSF gene. Owing to biosafety concerns, this genetic modification method is preferable over a retroviral infection approach because retroviral infection involves risks of development of competent recombinant retroviral particles in vivo. K562-hGM-CSF cells secreted approximately 3000 ng per 10 6 cells every 24 h, which is higher than previously reported values that range from 42 to 1403 ng per 10 6 cells every 24 h. 19, 22, 41, 42, 44, 45, 47 Although the GM-CSF threshold for an effective immunostimulation effect has been evaluated to be 36 ng per 10 6 cells every 24 h, 48 there are no clearly defined values reported for the site of cell injection. On the other hand, Serafini et al. 49 reported that a high-dose of GM-CSF could impair the immune response through the recruitment of myeloid suppressor cells. This inhibitory effect was attributed mainly to systemic rather than local secretion of GM-CSF. These experiments were performed in mouse models that do not give rise to a simplified calculation for the identification of the upper therapeutic limit in humans. The systemic inhibitory effect of GM-CSF may imply that the plasmatic dosage increases after injection of the GM-CSF-producing cells. Thus, the effective immunostimulatory range falls between the lower threshold described above and the value leading to a plasmatic change in GM-CSF dosage. Further studies to evaluate this range by measuring other For potent application of anti-tumor immunotherapy, there is a need to obtain a secretion of GM-CSF in vivo over a 3-to 7-day period, allowing time for dendritic cell recruitment and activation. 10, 48 Combining this requirement with safety concerns, we evaluated the secretion time profile of irradiated K562-hGM-CSF cells that either were in suspension or encapsulated. Irradiation provides a supplementary safety level over the enclosure of allogeneic cells that would be rejected by the host immune system in case of capsule breakage. Secretion results indicated a progressive decrease in GM-CSF secretion over a 14-day period that corresponds with the dying of irradiated cells. As the capsule cryopreservation is essential for clinical development, the secretion capacity of encapsulated cells frozen at day 1 or 3 after capsule loading was compared with that of the non-frozen control group. Until day 8, capsules frozen at day 1 showed lower GM-CSF secretion than capsules frozen at day 3 and the non-frozen control. These observations can be explained by the proliferation potential of the cells inside the capsule. With a cell density loading of 10 5 cells per capsule, there is sufficient volume for cell growth until the inner content of the capsule is occupied. This hypothesis was confirmed by histological analysis at day 1 and 3. After thawing, however, both groups reached comparable maximum secretion values, despite a lower value the day after thawing. This is probably due to partial cell death induced by the freezing/thawing procedures. Finally, histological analysis showed the development of necrotic debris inside the capsules appearing over time. This necrotic core is a typical feature associated with cell confinement within the device 50 and reflects the impaired transfer of oxygen and nutrients to the central part of the capsule. This phenomenon is undoubtedly increased by the malignant properties of the cells, having lost their contact proliferation inhibition. As the capsule irradiation before freezing/thawing seems a safer and more practical approach for human application, experiments with capsules intended for human application evaluated the GM-CSF secretion from capsules that had been irradiated before freezing. The results showed a secretion of 4300 ng GM-CSF per capsule every 24 h after 7 days in culture, which might be in the desired clinical range of secretion.
Preliminary testing of this approach was performed in mice. Encapsulated K562 cells showed a preserved cell survival after 5 days under such xenogeneic conditions, which is encouraging regarding future allogeneic applications. Mimicking potential human applications, the biological properties of GM-CSF were tested in an allogeneic model using encapsulated B16 mouse melanoma cells secreting mGM-CSF. Encapsulated B16-mGM-CSF cells released approximately 150 ng per capsule every 24 h. The difference in both secretion and cell density between encapsulated B16-mGM-CSF and K562-hGM-CSF cells may be explained by the presence of the polyvinyl alcohol matrix in the capsules containing the B16-mGM-CSF cells, decreasing the inner space for cell growth. Mice implanted with B16-mGM-CSF capsules showed a prompt inflammatory response around the capsules as early as 3 days post-implantation, confirming the potent and rapid effect of GM-CSF secretion. This inflammatory reaction undoubtedly impeded the efficient nutrient supply through the membrane, and might explain the lower density of enclosed cells after capsule retrieval. As previously mentioned, the aim of this strategy is to obtain an inflammatory reaction rather than long-term cell survival in the capsules. Further experiments will evaluate the ability of the encapsulation strategy for GM-CSF secretion to induce protective anti-tumor immunity. According to the efficiency of this process, it will be possible to modify the initial cytokine secretion values by changing the cell density loading and/or the capsule design.
This novel strategy affords greater control of the GM-CSF production rate as compared with previously described individualized gene transfer of autologous tumor cells. It will permit the separation of the source of GM-CSF and targeted antigens, and the conservation of the whole pattern of tumor-associated antigens by avoiding any genetic modification of these cells. The ability to freeze the GM-CSF-producing devices allows a simplification and standardization of the anti-tumor immunotherapy concept, which would consist of the combined implantation of a thawed capsule and irradiated autologous tumor cells.
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